determine the need for topical glucocorticoid therapy (TGC) in patients with JIA-U on systemic biological therapy in comparison to patients treated with methotrexate (MTX) only.

We have conducted longitudinal observational study with JIA-U patients in whom systemic immunomodulatory treatment (IMT: biologics and/or MTX) was introduced and who were followed at least 3 months in the period between 2011 and 2017. The data about the number of cells in the anterior chamber (AC) according to Standardization of Uveitis Nomenclature (SUN) Working Group criteria, about TGC and systemic therapy and JIA complications were collected on each examination. Generalized linear mixed models were used to analyze the relationships between treatment with biologics, MTX, TGC and the grade of inflammation in AC according to SUN criteria.

38 JIA-U patients (69 eyes) with median (range) age of 4.9 (2-15) years and follow up period of 209 (19-381) weeks were included. There were a total of 1205 examinations. At the first examination JIA-U was detected in 16 (42.1%) of patients, 59 (79.7%) of the eyes had $\leq 1+$ cells in the AC, and in 19 (50%) of JIA-U patients complications were already present. MTX was introduced in 23 (60.5%) JIA-U patients before the inclusion in the study, 8 (21%) has already received biologics, while in 4 (10.5%) prior systemic glucocorticoids were also used. Until the end of the study, all patients received MTX and 40% JIA-U were treated with biologics. The average number of TGC doses decreased from 3.74 at baseline to 0.72 in the 48th month.

After Friedman and the post hoc test a significant difference in the daily doses of TGC could be seen from the 12th month after application of systemic IMT. The number of daily doses of TGC as well as the degree of inflammation in AC per eye decreased over time. Using generalized linear mixed models it was shown that the treatment with biologics, but not with MTX and systemic glucocorticoids, was associated with lower intensity of TGC therapy.

Treatment with biologics and systemic glucocorticoids, but not with MTX, were associated with lower degree of inflammation in AC.

The results showed that the application of systemic biological therapy may result in less intensive TGC therapy, resulting in glucocorticoid-sparing potential, and reducing intraocular inflammation.

445

DETERMINING THE EFFECTIVENESS OF SYSTEMIC IMMUNOMODULATORY THERAPY IN THE TREATMENT OF PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS ASSOCIATED UVEITIS DEPENDING ON THE CHOSEN OUTCOME MEASURES

Barisic Kutija Marija, Sestan Mario*, Peric Sanja, Kifer Nastasia, Ivkic Petra Kristina, Galiot Delic Martina, Knezevic Josip, Held Martina, Frkovic Marijan, Jelusic Marija, Vukojevic Nenad. *University Hospital Centre Zagreb, Department of Paediatrics, University of Zagreb School of Medicine*

10.1136/archdischild-2021-europaediatrics.445

The number of patients with juvenile idiopathic arthritis associated uveitis (JIA-U) who need systemic immunomodulatory treatment (IMT) for disease control is small. Variabilities in the patient selection and the results on the effectiveness of IMT make it difficult to compare studies. We aimed to show on the same sample of JIA-U patients how different the

obtained levels of therapy efficacy are depending on the selected outcomes.

The longitudinal observational study with JIA-U patients treated with IMT was conducted at University Hospital Centre Zagreb in the period from 2011 to 2017.

We included 38 JIA-U patients aged 2 to 15 years and 69 eyes (7 patients had unilateral JIA-U). At baseline 46 (66.7%) eyes had grade $\leq 1+$ of inflammation in anterior chamber (AC) according to Standardization of Uveitis Nomenclature (SUN) Working Group criteria, 11 (15.9%) had grade 2+, 3 (4.4%) had grade 3+. 23 children (60.5%) had already received methotrexate (MTX), 8 (21.0%) biologics, 4 (10.5%) systemic glucocorticoids (GC). Topical glucocorticoids (TGC) in the form of drops were used in 61 (88.4%) eyes with a median of 4 daily doses, GC ointment in 75.4% of the eyes with a median of 1 dose. Until the end of the follow-up, all children received MTX, and 40% of them biologics. The results of the effectiveness of IMT are presented according to the reduction of the need for TGC and achieved level of inflammation in AC. In the first 12 months, among JIA-U patients treated with both biologics and MTX, in 65% of eyes there was no need for TGC therapy, in the 48th month in 50% of eyes, while the rest required 1-2 daily doses of TGC. At the end of the first year, with MTX and biological therapy 75% of eyes had grade 0 of inflammation and in 48th month 61.1%. In the 12th month in 75% of eyes a grade 0 of inflammation was achieved with ≤ 2 doses of TGC, and in the 48th month in 61.1%. According to milder criteria, in the 12th month 90% of the eyes have a degree of inflammation $\leq 0,5+$ with ≤ 2 doses of TGC, and in the 48th month all patients achieved this goal.

It was shown that the results of treatment outcomes during follow-up largely depend on the selected outcome measures. This will be important for future research because setting different limits can lead to a more favorable outcome.

446

SINGLE NUCLEOTIDE POLYMORPHISMS OF GENES HMGB1 AND AGER AND ITS ASSOCIATION WITH CLINICAL FEATURES OF IGA VASCULITIS

Martina Held*, Mateja Batnoci Varga, Mario Sestan, Matej Sapina, Nastasia Kifer, Danica Grguric, Kristina Crkvenac Gornik, Marijan Frkovic, Nena Arvaj, Jasenka Wagner, Marija Jelusic. *University Hospital Centre Zagreb, University of Zagreb School of Medicine*

10.1136/archdischild-2021-europaediatrics.446

IgA vasculitis (IgAV) is a disease in which genetic background also plays an important role. Some small studies have indicated the importance of variants in various non-HLA genes in the manifestation of different disease phenotypes. The aim of this research was to investigate single nucleotide polymorphisms (SNPs) of genes HMGB1 and AGER encoding for high mobility group box-1 (HMGB1) and receptor for advanced glycation endproducts (RAGE), both acting as mediators of inflammation, in the susceptibility and clinical features of patients with IgAV.

HMGB1 and RAGE gene polymorphisms were genotyped using a real-time polymerase chain reaction. The presence and frequency of polymorphisms in HMGB1 (rs2249825, rs1045411, rs1060348, rs1412125 and rs41369348) and RAGE (rs1800625, rs1800624, rs2070600 and rs3134940) were determined. Clinical data were collected from database